The PMC team is dedicated to promoting the understanding and adoption of personalized medicine concepts, services and products.

Lincoln D. Nadauld, M.D., Ph.D.

CEO, Culmination Bio

Dr. Nadauld recently co-founded and was appointed CEO of Culmination Bio, a biotechnology data and discovery company spun out of Intermountain Healthcare. Culmination utilizes electronic health data combined with biological data from millions of patient cases to discover better health, including novel diagnostic tests, therapeutic targets, and care process models.

Previously, Dr. Nadauld founded the Intermountain Precision Genomics program and successfully led the clinical implementation of precision health across Intermountain Healthcare’s 24 hospitals and 160 physician clinics while serving as Intermountain Healthcare’s Chief of Precision Health and Academics. Nadauld conceived of and led the Heredigene, Population Study — a collaborative effort to collect and perform whole genome sequencing on 500,000 participants in the Intermountain system.

Nadauld’s work has been recognized with the Utah Governor’s 32nd Annual Science Medal for Industry, which is the highest civilian award to be bestowed by the state of Utah and honors significant contributions to science and technology. Dr. Nadauld also received the 2020 C2 Catalyst for Precision Medicine award, honoring those who improve personalized treatment for cancer patients. He was also named a “Top 50 Healthcare Innovator” by Modern Healthcare. Dr. Nadauld has published extensively, with more than 50 peer-reviewed papers in leading scientific journals. He has also served as an editor for the Journal of Clinical Oncology-Precision Oncology.